OQL 051
Alternative Names: OQL-051Latest Information Update: 04 Sep 2023
At a glance
- Originator OnQuality Pharmaceuticals
- Class Antidiarrhoeals
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diarrhoea
Most Recent Events
- 06 Jun 2023 OnQuality Pharmaceuticals plans to initiate a phase I/II trial in Diarrhoea (Prevention, Chemotherapy-induced) in 2023
- 06 Jun 2023 The US FDA approves IND application for OQL 051 in Diarrhoea (Prevention, Chemotherapy-induced)
- 26 Oct 2022 Adverse events data from a preclinical trial in Diarrhoea presented at the 34th EORTC-NCI-AACR Symposium (EORTC-NCI-AACR - 2022)